At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 30, 2026 at 06:05 ET
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2024, with cash of $14.4M as of year-end. The company received FDA feedback requiring a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia, planned to start mid-2026, and raised $23M in cash through equity offerings, extending its runway into Q1-2027.
- Net loss narrowed to $19.9M in 2025 from $29.9M in 2024, with EPS improving from -$17.73 to -$5.48
- Cash and cash equivalents increased to $14.4M as of December 31, 2025, up from $13.5M in 2024
- FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine before NDA submission, delaying potential approval
- RECOVER-2 trial initiation planned for mid-2026, with U.S. enrollment expected to begin in Q3-2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access